Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network.
Wranke A, Lobato C, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Keskin O, Gherlan G, Abbas M, Ingiliz P, Muche M, Buti M, Jachs M, Vanwolleghem T, Cornberg M, Abbas Z, Yurdaydin C, Dörge P, Wedemeyer H; Hepatitis Delta International Network. Wranke A, et al. Among authors: yurdaydin c. Liver Int. 2024 Sep;44(9):2442-2457. doi: 10.1111/liv.16006. Epub 2024 Jun 18. Liver Int. 2024. PMID: 38888267
Non-invasive fibrosis score for hepatitis delta.
Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer H, Heidrich B. Lutterkort GL, et al. Among authors: yurdaydin c. Liver Int. 2017 Feb;37(2):196-204. doi: 10.1111/liv.13205. Epub 2016 Aug 10. Liver Int. 2017. PMID: 27428078
Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).
Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Wranke A, et al. Among authors: yurdaydin c. Liver Int. 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26. Liver Int. 2018. PMID: 28963781
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis.
Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; HIDT-1 Study Group. Zachou K, et al. Among authors: yurdaydin c. Liver Int. 2010 Mar;30(3):430-7. doi: 10.1111/j.1478-3231.2009.02140.x. Epub 2009 Oct 16. Liver Int. 2010. PMID: 19840253
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; HIDIT-1 study group. Grabowski J, et al. Among authors: yurdaydin c. Liver Int. 2011 Oct;31(9):1395-405. doi: 10.1111/j.1478-3231.2011.02593.x. Epub 2011 Jul 15. Liver Int. 2011. PMID: 21762356 Clinical Trial.
HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome.
Heidrich B, Serrano BC, Idilman R, Kabaçam G, Bremer B, Raupach R, Önder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydın C, Wedemeyer H. Heidrich B, et al. Among authors: yurdaydin c. Liver Int. 2012 Oct;32(9):1415-25. doi: 10.1111/j.1478-3231.2012.02831.x. Epub 2012 Jun 20. Liver Int. 2012. PMID: 22716112
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta.
Kabaçam G, Wedemeyer H, Savaş B, Keskin O, Dalekos G, Tabak F, Idilman R, Erhardt A, Yalçın K, Bozdayi MA, Bozkaya H, Manns M, Dienes H, Yurdaydın C; HIDIT-1 Study Group. Kabaçam G, et al. Among authors: yurdaydin c. Liver Int. 2014 Sep;34(8):1207-15. doi: 10.1111/liv.12376. Epub 2013 Dec 5. Liver Int. 2014. PMID: 24308704 Clinical Trial.
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
Yurdaydin C, Abbas Z, Buti M, Cornberg M, Esteban R, Etzion O, Gane EJ, Gish RG, Glenn JS, Hamid S, Heller T, Koh C, Lampertico P, Lurie Y, Manns M, Parana R, Rizzetto M, Urban S, Wedemeyer H; Hepatitis Delta International Network (HDIN). Yurdaydin C, et al. J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27. J Hepatol. 2019. PMID: 30982526 Review.
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta.
Wranke A, Hardtke S, Heidrich B, Dalekos G, Yalçin K, Tabak F, Gürel S, Çakaloğlu Y, Akarca US, Lammert F, Häussinger D, Müller T, Wöbse M, Manns MP, Idilman R, Cornberg M, Wedemeyer H, Yurdaydin C. Wranke A, et al. Among authors: yurdaydin c. J Viral Hepat. 2020 Dec;27(12):1359-1368. doi: 10.1111/jvh.13366. Epub 2020 Aug 11. J Viral Hepat. 2020. PMID: 32707605 Clinical Trial.
Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study.
Bremer B, Anastasiou OE, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Radu M, Idilman R, Manns MP, Cornberg M, Yurdaydin C, Wedemeyer H. Bremer B, et al. Among authors: yurdaydin c. Liver Int. 2021 Feb;41(2):295-299. doi: 10.1111/liv.14740. Epub 2020 Dec 5. Liver Int. 2021. PMID: 33217778
189 results